

# UC Irvine

## UC Irvine Previously Published Works

### Title

Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation.

### Permalink

<https://escholarship.org/uc/item/2vw1240d>

### Journal

Cell, 171(5)

### ISSN

0092-8674

### Authors

Dang, Eric V  
McDonald, Jeffrey G  
Russell, David W  
[et al.](#)

### Publication Date

2017-11-01

### DOI

10.1016/j.cell.2017.09.029

Peer reviewed



Published in final edited form as:

Cell. 2017 November 16; 171(5): 1057–1071.e11. doi:10.1016/j.cell.2017.09.029.

## Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation

Eric V. Dang<sup>1,\*</sup>, Jeffrey G. McDonald<sup>2</sup>, David W. Russell<sup>2</sup>, and Jason G. Cyster<sup>1,3,\*</sup>

<sup>1</sup>Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, CA 94143-0795, USA

<sup>2</sup>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

### Summary

Type I interferon restrains interleukin-1 $\beta$  (IL-1 $\beta$ )-driven inflammation in macrophages by upregulating cholesterol-25-hydroxylase (Ch25h) and repressing SREBP transcription factors. However, the molecular links between lipid metabolism and IL-1 $\beta$  production remain obscure. Here we demonstrate that production of 25-hydroxycholesterol (25-HC) by macrophages is required to prevent inflammasome activation by the DNA sensor protein absent in melanoma 2 (AIM2). We find that in response to bacterial infection or lipopolysaccharide (LPS) stimulation, macrophages upregulate Ch25h to maintain repression of SREBP2 activation and cholesterol synthesis. Increasing macrophage cholesterol content is sufficient to trigger IL-1 $\beta$  release in a crystal-independent but AIM2-dependent manner. Ch25h-deficiency results in cholesterol-dependent reduced mitochondrial respiratory capacity and release of mitochondrial DNA into the cytosol. *Ch25h*<sup>-/-</sup> *Aim2*<sup>-/-</sup> rescues the increased inflammasome activity observed in *Ch25h*<sup>-/-</sup>. Therefore, activated macrophages utilize 25-HC in an anti-inflammatory circuit that maintains mitochondrial integrity and prevents spurious AIM2 inflammasome activation.

### eTOC

Cholesterol overload directly triggers mitochondrial DNA release and activation of the AIM2 inflammasome in metabolic diseases


\*Correspondence: Jason.cyster@ucsf.edu, eric.dang@ucsf.edu.

<sup>3</sup>Lead contact

#### Author contributions

J.G.C. and E.V.D. conceived and designed the study. J.G.C. and E.V.D. designed and oversaw all experiments. E.V.D. performed the experiments. J.G.M. and D.W.R. performed the mass spectrometry experiments. J.G.C. and E.V.D. analyzed the data. J.G.C. and E.V.D. wrote the manuscript. J.G.M. and D.W.R. reviewed and edited the manuscript.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Keywords

Oxysterol; cholesterol; inflammasome; mitochondria; macrophage; IL-1 $\beta$ ; Ch25h; SREBP

## Introduction

Cholesterol is a crucial structural component of mammalian cell membranes. However, unlike fatty acids, cholesterol cannot be used as an energy source, necessitating feedback mechanisms to control cellular cholesterol content. The molecular basis for cholesterol feedback inhibition involves the Sterol Regulatory Element Binding Protein 2 (SREBP2) pathway, whereby increased endoplasmic reticulum (ER) cholesterol content causes the chaperone protein SCAP to bind more tightly to INSIG, which results in SREBP2 sequestration in the ER (Goldstein et al., 2006). In states of low ER cholesterol, SCAP dissociates from INSIG, allowing for translocation of the SCAP-SREBP2 complex to the Golgi apparatus where SREBP2 is cleaved (Goldstein et al., 2006). This releases the transcription factor domain of SREBP2, which translocates to the nucleus and activates the transcription of genes involved in cholesterol biosynthesis and uptake.

While cholesterol can inhibit sterol biosynthesis, the oxysterol 25-hydroxycholesterol (25-HC) is even more potent than cholesterol in its capacity to inhibit SREBP2 in biochemical studies (Goldstein et al., 2006). Whereas cholesterol is sensed by SCAP, 25-HC binds directly to INSIG causing increased association with SCAP-SREBP2. However, it has been unclear whether endogenously produced 25-HC contributes to cholesterol regulation in mammalian cells. Mice deficient in the enzyme cholesterol 25-hydroxylase (Ch25h), which produces 25-HC from cholesterol, do not show defects in baseline cholesterol homeostasis, raising the question of whether this metabolite has a physiologic function (McDonald and Russell, 2010).

It has recently been appreciated that Ch25h is an interferon (IFN)-inducible gene in macrophages. Stimulation of mouse bone marrow-derived macrophages (BMDMs) with LPS or polyI:C results in IFNAR1-dependent upregulation of Ch25h and 25-HC synthesis (Cyster et al., 2014). Consistent with the key role of type I interferon (IFN) in responses to

viruses, 25-HC has antiviral activity (Blanc et al., 2013; Cyster et al., 2014; Liu et al., 2013). Type I IFN additionally acts to inhibit IL-1 $\beta$ -driven inflammation (Cyster et al., 2014). This occurs by repression of *Il1b* transcription and inflammasome-dependent IL-1 $\beta$  processing (Guarda et al., 2011). Recent work suggests that the inhibitory action of type I IFN on IL-1 $\beta$  requires induction of Ch25h/25-HC (Reboldi et al., 2014).

Inflammasomes are multi-protein complexes that form within the cytosol following exposure to a wide variety of pathogen-derived stimuli (Rathinam and Fitzgerald, 2016).

Inflammasome activation requires recognition of ligand by a sensor protein followed by recruitment of the adaptor protein ASC (Rathinam and Fitzgerald, 2016). This results in ASC oligomerization and the recruitment and activation of caspase-1, a protease that processes pro-IL-1 $\beta$  into mature IL-1 $\beta$ . How 25-HC represses inflammasome activation has been unclear. The effects of Ch25h-deficiency on pro-IL-1 $\beta$  processing could be rescued by overexpression of INSIG1 or deletion of SCAP, suggesting a contribution by the SREBP pathway, but the nature of this contribution has not been defined (Reboldi et al., 2014).

Here, we describe a metabolic circuit that links regulation of cellular cholesterol content to the prevention of inflammasome activation. We find LPS-activated macrophages shut down cholesterol biosynthesis and decrease their cholesterol content in a Ch25h-dependent manner. Enforcement of increased macrophage cholesterol content after LPS stimulation is sufficient to drive inflammasome-dependent IL-1 $\beta$  production. Cholesterol-dependent inflammasome activation unexpectedly requires the cytosolic DNA sensor AIM2. Metabolic studies reveal that *Ch25h*<sup>-/-</sup> and cholesterol-loaded macrophages have impaired mitochondrial respiration and membrane polarization. This results in increased cytosolic mitochondrial DNA (mtDNA) content and depletion of mtDNA reduces cholesterol-dependent IL-1 $\beta$  release. Finally, we find that Ch25h/Aim2 double-deficiency reverses inflammasome activation caused by Ch25h-deficiency. These findings suggest that macrophage upregulation of 25-HC after pathogen recognition prevents cholesterol-dependent mitochondrial dysfunction and spurious crosstalk between mtDNA and the inflammasome.

## Results

### Ch25h controls IL-1 $\beta$ release and intracellular bacterial growth through ASC-dependent inflammasomes

*Ch25h*<sup>-/-</sup> BMDMs overproduce IL-1 $\beta$  in response to *Listeria monocytogenes* infection and show increased control of intracellular bacterial growth (Reboldi et al., 2014). To determine whether these responses were due to increased inflammasome activity, we generated *Ch25h*<sup>-/-</sup> *Asc*<sup>-/-</sup> mice. BMDMs from these mice and controls were treated with carrier (ethanol) or 25-HC (1 $\mu$ M), and infected with *L. monocytogenes* for 24 hr. *Ch25h*<sup>-/-</sup> *Asc*<sup>+/+</sup> BMDMs had increased production of IL-1 $\beta$ , which could be inhibited by addition of 25-HC as expected (Fig. 1A) (Reboldi et al., 2014). However, in the setting of ASC-deficiency, *Ch25h*<sup>-/-</sup> BMDMs showed no elevation in extracellular IL-1 $\beta$  and 25-HC addition to these cultures did not reduce IL-1 $\beta$  levels (Fig. 1B). We also observed decreased *L. monocytogenes* colony forming units (CFUs) in *Ch25h*<sup>-/-</sup> *Asc*<sup>+/+</sup> BMDMs, which could be

rescued by the addition of 25-HC (Fig. 1C). *Asc*<sup>-/-</sup> BMDMs showed an overall increase in *L. monocytogenes* CFUs and the protective effect of Ch25h-deficiency was lost (Fig. 1D).

In previous work we demonstrated that *Ch25h*<sup>-/-</sup> BMDMs overproduced IL-1 $\beta$  following exposure to LPS and the NLRP3 inflammasome activator ATP (Reboldi et al., 2014). Consistent with these observations, LPS+ATP treated *Ch25h*<sup>-/-</sup> cells produced increased IL-1 $\beta$  compared to controls (Fig. 1E). However, in the setting of *Asc*<sup>-/-</sup>, neither Ch25h genotype produced detectable IL-1 $\beta$ , ruling out the possibility that the increased cytokine production by *Ch25h*<sup>-/-</sup> cells was due to passive loss of membrane integrity (Fig. 1E). These data support a model in which IL-1 $\beta$  overproduction and decreased bacterial replication in *Ch25h*<sup>-/-</sup> BMDMs are due to increased activity of ASC-dependent inflammasomes. These observations led us to more deeply explore how Ch25h acts to restrain inflammasome activity.

### Ch25h and 25-HC enforce repression of the SREBP2 pathway and cholesterol synthesis in LPS-activated macrophages

Type I IFN has been described to repress the SREBP2 pathway in macrophages (Reboldi et al., 2014; York et al., 2015), but it is not clear to what extent this process depends on 25-HC. We therefore performed time-course analyses of cholesterol biosynthetic enzyme mRNA expression in control and *Ch25h*<sup>-/-</sup> BMDMs after stimulation with LPS. As expected, *Ch25h* transcript levels peaked ~4 hr post-LPS stimulation and subsequently declined (Fig. 2A) (Cyster et al., 2014). Similar *Ch25h* induction kinetics were observed following *L. monocytogenes* infection (Fig. S1A). The sterol biosynthetic enzymes *Hmgcs1*, *Lss*, *Dhcr24* and *Sqle* were initially repressed 2 hr post-LPS, regardless of the genetic status of Ch25h (Fig. 2A). However, by 8 hr of LPS stimulation, *Ch25h*<sup>-/-</sup> BMDMs showed increased expression of sterol biosynthetic enzyme mRNAs (Fig. 2A). Overexpression of these mRNAs was also observed after 8 hr of *L. monocytogenes* infection (Fig. S1B). These data suggest that Ch25h is induced in macrophages by bacterial sensing, and acts to repress sterol biosynthetic enzyme expression. However, Ch25h is not required for initial shutdown of the cholesterol biosynthesis pathway, but instead enforces sustained repression.

As a second approach to determine whether Ch25h represses cholesterol biosynthesis in activated macrophages, we performed liquid chromatography-mass spectrometry (LC-MS) for sterol biosynthetic intermediates after 8 hr of LPS treatment. *Ch25h*<sup>-/-</sup> BMDMs showed the expected reduction in 25-HC but showed increased levels of desmosterol, lanosterol, and 7-dehydrocholesterol, indicating that Ch25h acts to repress cholesterol biosynthesis pathway activity (Fig. 2B).

We next tested whether cholesterol content itself was altered in *Ch25h*<sup>-/-</sup> macrophages. Using a cholesterol fluorescence assay, *Ch25h*<sup>-/-</sup> BMDMs showed an initial increase in total cholesterol content compared to wild-type cells (Fig. 2C). LPS stimulation resulted in decreased cholesterol content in both genotypes by 4 hr, whereas only *Ch25h*<sup>-/-</sup> cells showed an increase in total cholesterol by 8 hr (Fig. 2C). Similarly, staining with filipin, a fluorescent cholesterol-binding antibiotic, showed higher fluorescence intensity in 8 hour LPS-activated *Ch25h*<sup>-/-</sup> macrophages (Fig. 2D). LC-MS analysis confirmed the increased cholesterol content (Fig. 2E). To determine whether *Ch25h*<sup>-/-</sup> macrophages increase their

cholesterol in vivo, we injected mice I.P. with LPS and sorted peritoneal macrophages after 8 hr. LPS caused *Ch25h*<sup>-/-</sup> macrophages to increase their cholesterol content, whereas cholesterol levels in controls remained constant (Fig. S1C).

The increased expression of SREBP2-responsive genes between 4 and 8 hr of LPS exposure in the *Ch25h*<sup>-/-</sup> setting suggested that there is a latent positive drive for cholesterol synthesis that is limited by 25-HC. mTORC1 signaling has been shown to drive SREBP1 and SREBP2 activation, and is activated by TLR stimulation (Düvel et al., 2010; Porstmann et al., 2008; Wang et al., 2011). We therefore tested whether this pathway was active in LPS stimulated BMDMs. Phospho-flow cytometry for total S6K1, pS6K1 (Thr389) and pS6 (Ser240/244) showed that LPS stimulation resulted in a time-dependent increase in mTORC1 activity (Fig. 2F). We confirmed that S6 phosphorylation during LPS stimulation was mTORC1-dependent since it was prevented by rapamycin treatment (Fig. S1D). Consistent with mTORC1 activity driving SREBP2 activation, the augmented expression of *Hmgcs1* mRNA in *Ch25h*<sup>-/-</sup> cells was largely prevented by rapamycin (Fig. 2G). Moreover, in accord with a connection between SREBP activity and IL-1 $\beta$  production (Reboldi et al., 2014), rapamycin reversed the overproduction of IL-1 $\beta$  in response to ATP in LPS stimulated *Ch25h*<sup>-/-</sup> macrophages, while having minimal effect on IL-1 $\beta$  production by *Ch25h*<sup>+/-</sup> cells (Fig. 2H). Taken together, these data indicate that *Ch25h*/25-HC are required in 8 hour LPS activated macrophages to antagonize mTORC1-induced SREBP2 pathway activity and prevent cholesterol over-accumulation.

### Non-crystalline cholesterol is sufficient to promote inflammasome activation

To determine whether increased cholesterol biosynthesis can be linked to inflammasome activation, we used a retrovirus system to transduce cDNAs expressing HMG-CoA reductase (*Hmgcr*) and dehydrocholesterol 24-reductase (*Dhcr24*), enzymes in the cholesterol biosynthetic pathway, into BMDMs. Using a fluorescent peptide that acts as a reporter for caspase-1 activity, we found that over-expression of either of these cDNAs resulted in increased inflammasome activity after 8 hr of LPS stimulation (Fig. 3A). Inflammasome activation in mouse macrophages typically requires addition of a 'second signal' (such as ATP) to engage an inflammasome sensor protein (Rathinam and Fitzgerald, 2016). However, the effect of increased expression of *Hmgcr* and *Dhcr24* mRNAs on caspase-1 was observed in the absence of an exogenous second signal. Attempts to measure IL-1 $\beta$  in the LPS-stimulated macrophage supernatant by ELISA were unsuccessful, consistent with a low amount of inflammasome activity. We therefore used an IL-17A-based IL-1 $\beta$  bioassay (Reboldi et al., 2014) to test whether cholesterol synthesis could drive inflammasome activation. Supernatants from BMDMs transduced with either *Hmgcr* or *Dhcr24* had augmented capacity to stimulate IL-17A production from T cells, whereas this capacity was lost in the setting of ASC-deficiency (Fig. 3B).

To determine whether cholesterol itself was involved in driving inflammasome activity, we treated BMDMs with LPS and cholesterol that had been solubilized by forming complexes with the carrier methyl- $\beta$ -cyclodextrin (MCD) at a 25:1 ratio of MCD:cholesterol (MCD-chol). Strikingly, treatment of LPS activated macrophages with 100 $\mu$ g/ml MCD-chol, a concentration typical of other studies (Robinson et al., 2014; York et al., 2015), was

sufficient to promote IL-1 $\beta$  production as measured by ELISA (Fig. 3C). A 10-fold lower dose of MCD-chol also triggered IL-1 $\beta$  production as detected using the IL-1 $\beta$  bioassay (Fig. 3D).

Previous work has suggested that the NLRP3 inflammasome is activated by cholesterol crystals in macrophages (Franklin et al., 2016). To determine whether our observed IL-1 $\beta$  release in response to MCD-chol was due to crystal formation, we noted that crystalline inflammasome activators depend on phagocytic uptake (Hornung et al., 2008). We treated LPS-activated BMDMs with cytochalasin D to inhibit actin polymerization and challenged them with MCD-chol, ATP, or alum. Whereas IL-1 $\beta$  release by the crystalline activator alum was blocked by cytochalasin D treatment, IL-1 $\beta$  release in response to MCD-chol or ATP was unaffected, providing evidence that MCD-chol is acting in a soluble fashion (Fig. 3E).

To determine whether 25-HC can prevent cholesterol-dependent IL-1 $\beta$  release, we reconstituted *Ch25h*<sup>-/-</sup> BMDMs with either wild-type Ch25h, a mutant Ch25h that cannot synthesize 25-HC (Reboldi et al., 2014), or empty vector. Overexpression of Ch25h could repress the sterol biosynthesis enzyme *Sqle* mRNA, whereas vector and Ch25hmut had no effect, confirming the functional status of these constructs (Fig. S2A). We found that while overexpression of Ch25h had a small capacity to diminish IL-1 $\beta$  release in response to ATP, it more substantially reduced the capacity of MCD-chol to stimulate IL-1 $\beta$  release, whereas Ch25hmut had no effect (Fig. 3F). In addition to its ability to inhibit SREBP2 activation, 25-HC could possibly protect cells from cholesterol overloading by acting as an LXR agonist. Reconstitution of LXR $\alpha/\beta$  double knockout BMDMs with wild type versus mutant Ch25h showed the same repressive effect on MCD-chol-dependent IL-1 $\beta$  release, suggesting that this phenomenon does not involve LXRs (Fig. S2B). These observations provide further evidence that a key function of Ch25h/25-HC induction in activated macrophages is to prevent cholesterol-dependent IL-1 $\beta$  production.

### Cholesterol-dependent IL-1 $\beta$ release requires the AIM2 inflammasome

Mitochondrial reactive oxygen species (mtROS) have been implicated as activators of the NLRP3 inflammasome in response to a diverse range of stimuli (Zhou et al., 2011). Additionally, diseases associated with cholesterol dysregulation have been shown to induce mtROS (Kennedy et al., 2014). Therefore, we tested whether mtROS induction could be responsible for cholesterol-dependent IL-1 $\beta$  production. While LPS plus ATP treatment increased mtROS as expected (Yu et al., 2014; Zhou et al., 2011) *Ch25h*<sup>-/-</sup> BMDMs had heightened mtROS production after compared to control BMDMs (Fig. 4A). Retroviral reconstitution of *Ch25h*<sup>-/-</sup> BMDMs with Ch25h reduced mtROS, whereas Ch25hmut showed no effect (Fig. 4B). Treatment of *Ch25h*<sup>+/-</sup> and *Ch25h*<sup>-/-</sup> BMDMs with the mtROS scavenger MitoTEMPO inhibited IL-1 $\beta$  in both genotypes (Fig. S3A). Furthermore, treatment of uninfected BMDMs with LPS plus MCD-chol resulted in increased mtROS compared to LPS alone, consistent with data suggesting that elevated cholesterol content can cause mitochondrial dysfunction (Fig. 4C). Moreover, using a 293T NLRP3 inflammasome reconstitution system we found that SREBP2 over-expression was capable of promoting IL-1 $\beta$  cleavage and release (Fig. S3B, S3C, S3D). Combined, these observations suggested that IL-1 $\beta$  release by macrophages following cholesterol accumulation would occur via the

NLRP3 inflammasome. Surprisingly, however, BMDMs lacking NLRP3 had no defect in IL-1 $\beta$  production in response to LPS plus MCD-chol treatment, whereas these cells failed to respond to LPS plus ATP (Fig. 4D).

To test whether the observed IL-1 $\beta$  release in MCD-chol challenged BMDMs was an inflammasome-dependent process we challenged *Asc*<sup>-/-</sup> and *Casp-1/11*<sup>-/-</sup> BMDMs with LPS and MCD-chol. *Asc*<sup>-/-</sup> (Fig. 4E) and *Casp-1/11*<sup>-/-</sup> (Fig. 4F) BMDMs showed complete abrogation of IL-1 $\beta$  production in response to cholesterol, establishing that this process was indeed inflammasome-dependent.

To identify the relevant sensor protein required for cholesterol-dependent IL-1 $\beta$  production, we challenged *Nlr4*<sup>-/-</sup>, *Casp11*<sup>-/-</sup>, and *Aim2*<sup>-/-</sup> BMDMs with LPS and MCD-Chol. *Nlr4*<sup>-/-</sup> (Fig. 4G) and *Casp11*<sup>-/-</sup> (Fig. 4H) BMDMs showed no difference in IL-1 $\beta$  production in response to cholesterol challenge. On the other hand, *Aim2*<sup>-/-</sup> BMDMs showed a striking reduction in IL-1 $\beta$  release under these conditions (Fig. 4I). Given that different inflammasomes can cooperate in some contexts, we tested whether the low amount of remaining inflammasome activity in *Aim2*<sup>-/-</sup> BMDMs involved NLRP3. Consistent with a partially redundant contribution of NLRP3 to cholesterol-induced IL-1 $\beta$  release, *Aim2*<sup>-/-</sup>*Nlrp3*<sup>-/-</sup> BMDMs showed a near complete loss of secreted IL-1 $\beta$  when compared with *Casp1/11*<sup>-/-</sup> BMDMs (Fig. 4J).

Neutrophilic peritonitis is a well-described model system for *in vivo* assessment of inflammasome activation. To determine whether cholesterol could drive inflammasome activation *in vivo*, we injected LPS, LPS and MCD-chol, or LPS and Alum I.P. Strikingly, MCD-chol was as efficacious as Alum in causing neutrophil accumulation in the peritoneum (Fig. 5A and 5B). To determine whether AIM2 inflammasome activation was required for neutrophilic peritonitis, lethally irradiated mice were reconstituted with wild-type or *Aim2*<sup>-/-</sup> BM. We found that hematopoietic AIM2-deficiency resulted in a reduction in MCD-chol induced neutrophil recruitment (Fig. 5C and 5D). We also generated chimeras using *Nlrp3*<sup>-/-</sup>, or *Casp1/11*<sup>-/-</sup> BM; consistent with our observations in BMDMs, lack of NLRP3 had no effect on neutrophil recruitment following MCD-chol challenge, whereas caspase-1 deletion resulted in the expected strong reduction (Fig. 5E).

### Ch25h-deficiency results in impaired mitochondrial metabolism

The requirement for AIM2, a DNA sensor, in cholesterol-dependent inflammasome activation led us to consider the possibility that dysregulation of cellular cholesterol homeostasis results in release of host DNA into the cytosol. Mitochondria contain multiple copies of mtDNA that encodes for components of the oxidative metabolism machinery. A number of recent studies have demonstrated that mitochondrial dysfunction can lead to mtDNA release into the cytosol (Rongvaux et al., 2014; West et al., 2015; White et al., 2014). Additionally, baseline mitochondrial cholesterol levels are low, and increased mitochondrial cholesterol accumulation is associated with impaired mitochondrial function (Kennedy et al., 2014). Due to these observations and our findings that Ch25h-deficiency and cholesterol accumulation cause mtROS production, we asked whether the altered cholesterol homeostasis caused by Ch25h-deficiency resulted in impaired mitochondrial function in macrophages. We first assessed mitochondrial respiration and abundance using



Mitotracker Deep Red and Mitotracker Green dyes, respectively, by flow cytometry. *Ch25h*<sup>-/-</sup> BMDMs showed diminished Mitotracker Deep Red staining compared to control macrophages after 8 hr of LPS stimulation (Fig. 6A). Mitotracker Deep Red staining could be rescued by reconstituting *Ch25h*<sup>-/-</sup> BMDMs with Ch25h, but not Ch25hmut (Fig. 6B). Mitotracker Green staining also showed a small but statistically significant decrease in 8 hour LPS-stimulated *Ch25h*<sup>-/-</sup> BMDMs (Fig. 6C). This defect could also be rescued by wild-type but not mutant Ch25h (Fig. 6D). We additionally found that *Ch25h*<sup>-/-</sup> macrophages showed diminished Mitotracker Deep Red and Mitotracker Green staining in response to 8 hr of *L. monocytogenes* infection (Fig. S4A and S4B).

To determine whether increased cholesterol content was sufficient to explain the Mitotracker staining effects in *Ch25h*<sup>-/-</sup> BMDMs, we treated *Asc*<sup>+/+</sup> and *Asc*<sup>-/-</sup> BMDMs with LPS and MCD-chol and measured Mitotracker staining. Both Mitotracker Deep Red and Mitotracker Green staining were diminished by increasing cellular cholesterol content (Fig. S4C and S4D). Importantly, *Asc*<sup>-/-</sup> BMDMs also showed decreased Mitotracker staining, demonstrating that this effect was not secondary to increased inflammasome activation (Yu et al., 2014). As a second test of whether increased cholesterol content was sufficient to affect Mitotracker staining, we again transduced BMDMs with *Hmgcr*, or *Dhcr24* and stimulated these macrophages with LPS. Both Mitotracker Deep Red and Mitotracker Green staining were diminished by enzyme overexpression (Fig. S4E and S4F). To determine whether cholesterol efflux could rescue Mitotracker staining, we treated macrophages with HDL or the LXR agonist GW3965 along with LPS. The diminished Mitotracker Deep Red staining in *Ch25h*<sup>-/-</sup> cells was rescued by both HDL and GW3965, further supporting a role for cholesterol in this outcome (Fig. S4G).

Mitochondrial dysfunction is often associated with alterations in the ion potential of the inner membrane (Shimida et al., 2012). We therefore tested whether Ch25h affected mitochondrial membrane potential using tetramethylrhodamine methyl ester (TMRM), a cationic dye that becomes sequestered in the mitochondrial matrix in amounts directly proportional to the membrane potential. LPS stimulation resulted in diminished TMRM staining in *Ch25h*<sup>-/-</sup> macrophages compared to controls (Fig. 6E). TMRM staining could be rescued by retroviral transduction of *Ch25h*<sup>-/-</sup> macrophages with active but not mutant Ch25h enzyme (Fig. 6F). Diminished TMRM staining was also observed in *Ch25h*<sup>-/-</sup> macrophages after *L. monocytogenes* infection (Fig. S4H).

As another approach to assess mitochondrial function we utilized the Seahorse assay to measure oxygen consumption by BMDMs after 8 hr of LPS stimulation. *Ch25h*<sup>-/-</sup> macrophages showed a decreased basal oxygen consumption rate (OCR) compared to wild-type cells (Fig. 6G and 6H). More strikingly, BMDMs lacking Ch25h showed impaired spare respiratory capacity (SRC) after FCCP treatment, suggesting that maximal mitochondrial respiration is impaired in settings of altered cholesterol homeostasis (Fig. 6G). The decrease in basal oxygen consumption rate in *Ch25h*<sup>-/-</sup> macrophages was also coupled to an increased extracellular acidification rate (ECAR), suggesting that these cells were metabolically reprogrammed towards aerobic glycolysis (Fig. 6H). To determine whether impaired mitochondrial respiration in the absence of Ch25h could be explained by increased cholesterol content, we treated BMDMs with MCD-chol and again performed

Seahorse analysis. Consistent with our hypothesis, cholesterol loaded macrophages also showed impaired basal OCR as well as diminished SRC (Fig. S4I).

To test whether *Ch25h*<sup>-/-</sup> macrophages showed signs of mitochondrial dysfunction in vivo, we intraperitoneally injected control and *Ch25h*<sup>-/-</sup> mice with saline or LPS for 8 hr and assessed Mitotracker staining on peritoneal macrophages. While saline treated mice showed no difference between genotypes, we observed diminished Mitotracker Deep Red and Mitotracker Green staining in peritoneal macrophages derived from *Ch25h*<sup>-/-</sup> mice after LPS treatment (Fig. 6I, 6J, and S4J).

### **Increased mitochondrial cholesterol content results in cytosolic mtDNA accumulation and inflammasome activation**

Given our observation that *Ch25h*<sup>-/-</sup> macrophages showed increased cellular cholesterol and mitochondrial dysfunction, we asked whether these cells had increased mitochondrial cholesterol content. We used an immunoprecipitation system with anti-Tomm22 coupled beads to isolate mitochondria and mitochondrial-associated membrane (MAM) from either control or 8 hour LPS-stimulated BMDMs. Immunoblots of these fractions showed an expected enrichment in the outer mitochondrial membrane protein Tomm20, depletion of the cytosolic protein  $\beta$ -tubulin, and partial depletion of the ER/MAM protein calreticulin compared to whole cell extracts (Fig. S5A). The incomplete depletion of calreticulin was most likely due to MAM contamination (Hayashi et al., 2007). We saw that *Ch25h*<sup>-/-</sup> BMDMs show increased mitochondrial/MAM cholesterol content after LPS stimulation compared to controls (Fig. 7A). Additionally, we found that reconstitution of *Ch25h*<sup>-/-</sup> macrophages with wild type but not mutant Ch25h enzyme could decrease mitochondrial/MAM cholesterol levels (Fig 7B). Mitochondrial/MAM cholesterol content was also increased in BMDMs treated with LPS and MCD-Chol (Fig. S5B). These findings together with the evidence of mitochondrial damage and the requirement for AIM2 in cholesterol-dependent inflammasome activation led us to test whether Ch25h-deficiency and cholesterol loading increased cytosolic mtDNA. We stimulated BMDMs with either vehicle or LPS for 8 hr and then extracted cytosolic DNA. qPCR analysis for mtDNA and nuclear DNA (nucDNA) showed that *Ch25h*<sup>-/-</sup> BMDMs increased their cytosolic mtDNA, but not nucDNA, after LPS stimulation (Fig. 7C). Additionally, cholesterol treatment of BMDMs was sufficient to drive increased mtDNA but not nucDNA accumulation in the cytosol (Fig. S5C). Consistent with our observation that rapamycin blocks the SREBP2 pathway in *Ch25h*<sup>-/-</sup> macrophages, we found that rapamycin could also decrease mitochondrial cholesterol accumulation and cytosolic mtDNA in LPS-treated *Ch25h*<sup>-/-</sup> BMDMs (Fig. S5D, S5E). A number of recent studies have demonstrated that cytosolic release of mtDNA can activate the cGAS/STING DNA sensing pathway that triggers the production of type I IFNs (Rongvaux et al., 2014; West et al., 2015; White et al., 2014; Aguirre et al, 2017; Sun et al., 2017). Therefore we asked whether cholesterol treatment of BMDMs would show evidence of type I IFN induction. However, under the LPS stimulation condition there is a large amount of TLR4-mediated IFN production and induction of interferon-stimulated genes (ISGs) (Fig. S5F), and we were unable to detect increased ISG expression with LPS plus MCD-chol stimulation (Supp. Fig. S5F).

The release of mtDNA into the cytosol of *Ch25h*<sup>-/-</sup> macrophages would require an increase in mitochondrial membrane permeability. To test this directly, we assessed whether *Ch25h*<sup>-/-</sup> macrophages had increased cytochrome C (cyt C), a protein normally sequestered between the mitochondrial inner and outer membrane, in the cytosol (Campos et al., 2006). Intracellular staining for cyt C in non-digitonin treated cells detected both cytosolic and mitochondrial cyt C. This signal was then compared to that for cells that were digitonin-treated, causing cytosolic cyt C to leak out, prior to intracellular staining. We found that LPS treated, *Ch25h*<sup>-/-</sup> cells showed a preferential loss of cyt C after digitonin treatment compared to *Ch25h*<sup>+/-</sup> cells (Fig. 7D).

To functionally link increased cytosolic mtDNA accumulation with inflammasome activation, we used two approaches to deplete mtDNA from BMDMs. Ethidium bromide (EtBr) is a DNA intercalating agent that has been used in a number of studies to deplete mtDNA (Rongvaux et al., 2014; Shimada et al., 2012; Zhong et al., 2016). 2'-3'-dideoxycytidine (ddC) is a nucleoside analogue that has selectivity for the mtDNA polymerase (Chen and Cheng, 1989; Rongvaux et al., 2014). We cultured BMDMs for 7 days in the presence of either EtBr or ddC; both conditions resulted in an approximately 66% loss of cellular mtDNA (Fig. 7E). Strikingly, after stimulating these cells with LPS alone, LPS plus MCD-chol, or LPS plus ATP we found that mtDNA depletion selectively reduced IL-1 $\beta$  release in response to cholesterol but not ATP treatment (Fig. 7F). These results suggest that dysregulated cholesterol metabolism results in mitochondrial damage, leading to mtDNA-dependent AIM2 inflammasome activation.

To directly test whether Ch25h-deficiency leads to AIM2-dependent inflammasome activation, we generated *Ch25h*<sup>-/-</sup> *Aim2*<sup>-/-</sup> mice. BMDMs from these mice and their matched controls were stimulated with LPS and supernatants tested for IL-17A induction in the IL-1 $\beta$  bioassay. *Ch25h*<sup>-/-</sup> cells showed increased IL-1 $\beta$  bioactivity as expected (Fig. 7G). However, deletion of AIM2 in the setting of Ch25h-deficiency reduced the IL-1 $\beta$  bioactivity back to Ch25h-sufficient levels (Fig. 7G).

As a second test of whether increased inflammasome activity in *Ch25h*<sup>-/-</sup> macrophages required AIM2, we stimulated BMDMs with LPS+ATP, a classic NLRP3 activator, and measured IL-1 $\beta$  by ELISA. We again observed increased IL-1 $\beta$  production in *Ch25h*<sup>-/-</sup> macrophages (Fig. 7H). Importantly, deletion of AIM2 in the setting of Ch25h-deficiency resulted in diminished IL-1 $\beta$  production whereas AIM2-deficiency did not alter the response of Ch25h-sufficient cells (Fig. 7H). These results suggest that Ch25h deficiency creates a partial switch in the inflammasome sensor requirement for responses to ATP. We additionally tested the inflammasome response of these cells to FlaTOX, an NLRC4 activator, and poly(dA:dT), an AIM2-activator. With FlaTOX treatment, Ch25h/AIM2 double-deficiency again rescued the overproduction of IL-1 $\beta$  observed in *Ch25h*<sup>-/-</sup> macrophages (Fig. S5G), whereas the response to poly(dA:dT) was abrogated in the setting of AIM2-deficiency regardless of Ch25h status, as was expected (Fig. S5H).

We next tested whether the enhanced protection from *Listeria* infection observed in *Ch25h*<sup>-/-</sup> macrophages (Fig. 1C) required AIM2. *Listeria* engages multiple inflammasome pathways (NLRP3, AIM2, NLRC4) (Wu et al., 2010) and in accord with this knowledge,

AIM2 deficiency led to increased *Listeria* growth (Fig. 7I). Importantly, however, in contrast to the protective effect of Ch25h loss from *Aim2*<sup>+/+</sup> macrophages, Ch25h-deficiency did not lead to a significant protection of *Aim2*<sup>-/-</sup> macrophages (Fig. 7I). These findings provide evidence in the context of a bacterial infection that Ch25h restricts AIM2-inflammasome activation.

Caspase-1 activation has been suggested to cause mitochondrial damage under some conditions (Yu et al., 2014). To test whether caspase-1 activity was required for AIM2 inflammasome activation in the setting of Ch25h-deficiency we stimulated BMDMs with LPS and treated with FLICA to irreversibly inhibit caspase-1 and also to allow visualization of inflammasome specks. Consistent with our observations that IL-1 $\beta$  production in response to LPS without 'signal 2' is below the limit of detection of ELISA, speck formation was rare in this condition. However, speck formation was increased in *Ch25h*<sup>-/-</sup> BMDMs, and this effect was rescued by AIM2 double-deficiency (Fig. S5I). These data suggest that caspase-1 activity is not required for AIM2 inflammasome formation in the setting of Ch25h-deficiency.

Finally, to determine whether AIM2 is required for the overproduction of IL-1 $\beta$  from *Ch25h*<sup>-/-</sup> hematopoietic cells *in vivo*, BM chimeric mice were generated. Following reconstitution the mice were injected intravenously with saline or LPS for 8 hr and then serum was harvested for cytokine analysis. Consistent with our previous results, we saw increased serum IL-1 $\beta$  in LPS-challenged *Ch25h*<sup>-/-</sup> BM chimeras (Reboldi et al, 2014) (Fig. 7I). In keeping with our *in vitro* observations, *Ch25h*<sup>-/-</sup> *Aim2*<sup>-/-</sup> BM chimeras had diminished serum IL-1 $\beta$  levels that were similar to Ch25h-sufficient levels (Fig. 7I). Collectively, these data suggest that Ch25h deficiency results in altered nucleic acid compartmentalization that triggers inflammation via AIM2.

## Discussion

In this study, we identify a metabolic circuit that is crucial for limiting inflammasome activity in activated macrophages. We show that induction of Ch25h by type I IFN plays a key role in restricting the SREBP2 pathway and cholesterol biosynthesis in the context of bacterial infection and LPS exposure. These observations are consistent with a number of recent studies that have demonstrated the ability of type I IFNs to repress cholesterol metabolism (Robertson et al., 2016)(York et al, 2015). However, our study suggests that Ch25h is not required to initiate suppression of sterol biosynthesis, but is instead required to maintain this effect over time. Consistent with work suggesting that mTORC1 signaling can drive SREBP2 activation (Düvel et al., 2010; Porstmann et al., 2008; Wang et al., 2011), we find that the overexpression of cholesterol biosynthesis enzymes in *Ch25h*<sup>-/-</sup> cells is rapamycin-sensitive. Both TCR-activated T cells and LPS-activated macrophages switch to aerobic glycolysis and engage mTORC1 signaling due to the mutual requirement of both cell types to massively increase protein synthesis capacity (Powell et al., 2012). However, activated T cells undergo rapid proliferation and thus are constantly using cholesterol to synthesize new cellular membranes, whereas macrophages are largely quiescent and therefore susceptible to mTORC1-driven cholesterol over-accumulation. We speculate that the acute induction of Ch25h in macrophages allows them to selectively utilize the protein

synthesis arm of mTORC1 signaling to produce cytokines and other important anti-microbial factors, while preventing cholesterol buildup and cellular pathology.

Inflammasome sensor proteins are positioned in the cytosol and this allows them to distinguish highly pathogenic bacteria from commensals due to the propensity of pathogens to break out of the phagosome. Because mitochondria are derived from endosymbiotic bacteria, they contain a number of potential danger-associated molecular patterns (DAMPs) that could be released into the cytosol to trigger inflammation. Cholesterol levels in mitochondria are about 40-fold lower than in the plasma membrane and these organelles are highly sensitive to cellular cholesterol alterations (Bosch et al., 2011; Marí et al., 2006; Martin et al., 2016). We rationalize that Ch25h upregulation upon extracellular bacterial sensing helps prevent cholesterol-dependent mitochondrial damage and release of endogenous DAMPS into the cytosol. In the absence of this pathway, mitochondrial membrane damage can lead to increases in cytosolic DNA, resulting in engagement of the AIM2 inflammasome and exaggerated IL-1 $\beta$  production.

It is notable that Ch25h-deficiency augments the response to multiple types of inflammasome activators. This could in principle be due to a general antagonistic effect of 25-HC on inflammasome assembly. However, we find that this augmented inflammasome activity is reversed in the setting of AIM2 deletion, suggesting that the broad overproduction of IL-1 $\beta$  is due to ectopic AIM2 activation. This may indicate that the altered metabolic state occurring in the absence of Ch25h makes cells poised to engage AIM2 inflammasomes. With further mitochondrial stress resulting from infection or potentially dietary lipid overload, sufficient mtDNA may become released to engage the AIM2 inflammasome. While our data establish a temporal requirement for Ch25h to restrain IL-1 $\beta$  production by TLR-activated macrophages, Ch25h expression is not preventing IL-1 $\beta$  production. Rather, we suggest that by maintaining the metabolic health of the cell, Ch25h and 25-HC are helping to ensure that macrophages make a beneficial and not pathological amount of IL-1 $\beta$ . While we have mostly tested this circuit in the context of TLR agonists or bacterial infection, Ch25h may also be important in controlling IL-1 $\beta$  production during metabolic inflammation, where it would be critical to keep cytokine concentrations below a pathologic threshold.

Beyond repressing cholesterol biosynthesis through SREBP2, our data suggest that 25-HC can counter mitotoxic effects of cholesterol accumulation, based on the capacity of Ch25h overexpression to block IL-1 $\beta$  release in response to exogenous cholesterol. The LXR family members were intriguing candidates for this effect, since they promote cholesterol efflux through upregulation of ABCA1 and ABCG1, and tentative evidence suggests that 25-HC does have some ligand activity for these nuclear hormone receptors (Cyster et al., 2014). However, Ch25h retained its capacity to blunt cholesterol-dependent effects when expressed in LXR $\alpha/\beta$  double knockout macrophages. We speculate that this activity of Ch25h may instead be related to the capacity of 25-HC to act as an allosteric activator of ACAT1, an enzyme that esterifies cholesterol to allow storage in lipid droplets (Metherall et al., 1991). However, there is at present no genetic evidence that ACAT1 activity is affected by endogenously produced 25-HC. Future work will be needed to examine effects of 25-HC on cholesterol esterification in activated macrophages.

AIM2 is a well-described sensor of cytosolic DNA that can trigger inflammasome activation (Rathinam and Fitzgerald, 2016). Activation of this sensing pathway is usually described in the context of pathogen-derived nucleic acids that enter the host cell cytosol (Rathinam and Fitzgerald, 2016). However, the AIM2 HIN-200 domain is not sequence-specific, and therefore host DNA represents a potential pool of ligand if the nucleic acid is de-compartmentalized. Cytosolic release of mtDNA can trigger the cGAS-dependent DNA sensing pathway in the context of caspase-3/7- and TFAM-deficiency (Rongvaux et al., 2014; West et al., 2015; White et al., 2014) and in dengue virus infected cells (Aguirre et al., 2017; Sun et al., 2017), but there are few examples of AIM2 activation by mtDNA. A number of studies have suggested that oxidized mtDNA can act as a ligand for NLRP3 (Nakahira et al., 2011; Shimada et al., 2012), which is consistent with our findings that NLRP3 redundantly contributes to cholesterol-dependent IL-1 $\beta$  production. Interestingly, the cited studies had to use AIM2-deficient macrophages to reveal NLRP3-dependent effects in response to transfected mtDNA; but to our knowledge there are no prior examples of endogenous mtDNA release triggering AIM2. It remains an open question as to how exactly cholesterol buildup leads to cytosolic mtDNA release in macrophages. It would be of interest to determine whether this process involves Bax/Bak-mediated membrane permeabilization, as there is conflicting evidence on whether cholesterol promotes or antagonizes Bax oligomerization and pore formation (Christenson et al., 2008; Montero et al., 2010). Cholesterol-induced reduced membrane fluidity and increased oxidative stress might also lead to other forms of mitochondrial membrane damage (Kennedy et al., 2014; Martin et al., 2016). Given the complexities associated with determining the exact nucleic acid sources that trigger cytosolic DNA sensor proteins, and the large size of the nuclear genome, our studies do not exclude the possibility that increased cholesterol content of intracellular membranes causes cytosolic accumulation of nuclear DNA as an additional AIM2 ligand.

Finally, while we believe Ch25h upregulation by type I IFN represents a physiological circuit that prevents mtDNA from engaging AIM2, these observations raise additional questions about the role of cholesterol in driving inflammation in chronic diseases like obesity and metabolic syndrome. A number of studies have implicated inflammatory cytokines like TNF and IL-1 $\beta$  in promoting insulin resistance in high-fat diet (HFD) conditions (de Luca and Olefsky, 2008). Additionally, inflammasomes have been suggested to play a causal role in metabolic inflammation (Stienstra et al., 2011; Vandanmagsar et al., 2011). However, the exact mechanisms underlying lipid-driven inflammation are still unclear. Ceramide accumulation has been argued to engage the NLRP3 inflammasome during HFD (Vandanmagsar et al., 2011), but little is known about the role of cholesterol-driven inflammation in obesity, despite the fact that LDL and HDL levels have been used as risk factors for atherosclerosis for decades. A limited number of reports have noted a connection between cholesterol-dependent mitochondrial dysfunction under high fat conditions and development of metabolic diseases (Martin et al., 2016). While it is recognized that cholesterol levels in cells are tightly controlled and not readily altered by changes in dietary cholesterol, it will be of interest to determine whether Ch25h-deficient mice have exacerbated inflammatory responses to HFD, and whether AIM2 deficiency blunts the inflammatory effects of HFD.

In conclusion, the studies described herein provide mechanistic insight into how regulation of macrophage cholesterol homeostasis during pathogen sensing integrates with inflammasome regulation, and they advance our understanding of how cellular cholesterol can act as an inflammatory driver.

## STAR METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Fixable viability dye eFluor780	eBioscience	Cat# 65-0865-14
Anti-mouse IL-17A Monoclonal Antibody (eBio17B7), PE	eBioscience	Cat# 12-7177-81
Anti-mouse CD4 Monoclonal Antibody (RM4-5), APC	Tonbo Biosciences	Cat# 20-0042-U100
Anti-mouse TCR $\beta$ Monoclonal Antibody (H57-597), Pacific Blue	Biolegend	Cat# 109226
Fixable viability dye eFluor780	eBioscience	Cat# 65-0865-14
Anti-mouse LDLR Polyclonal Antibody, PE	Sino Biological	Cat# 50305-R032-P-25
Anti-mouse CD4 Monoclonal Antibody (RM4-5), APC	Tonbo Biosciences	Cat# 20-0042-U100
Anti-mouse TCR $\beta$ Monoclonal Antibody (H57-597), Pacific Blue	Biolegend	Cat# 109226
Anti-mouse F4/80 Monoclonal Antibody (BM8.1), APC	Tonbo Biosciences	Cat# 20-4801-U100
Anti-Phospho-S6 Ribosomal Protein (Ser240/244) Monoclonal Antibody (D68F8)	Cell Signaling Technologies	Cat# 5364S
Anti-Phospho-p70 S6 Kinase (Thr389) Monoclonal Antibody (108D2)	Cell Signaling Technologies	Cat# 9234S
Anti-p70 S6 Kinase Monoclonal Antibody (49D7)	Cell Signaling Technologies	Cat# 9234T
Anti-mouse Cytochrome C Monoclonal Antibody (6H2.4), Alexa488	Biolegend	Cat# 612308
Anti-mouse NLRP3/NALP3 Monoclonal Antibody (Cryo-2)	Adipogen	Cat# AG-20B-0014-C100
Anti-mouse Asc Polyclonal Antibody (AL177)	Adipogen	Cat# AG-25B-0006-C100
Anti-mouse Caspase-1 Polyclonal Antibody (M-20)	Santa Cruz Biotechnology	Cat# sc-514
Anti-mouse Tomm20 Polyclonal Antibody	One World Lab	Cat# C16678
Anti-mouse $\alpha$ -Tubulin Monoclonal Antibody (DM1A), Biotin	eBioscience	Cat# 13-4502-80
Bacterial and Virus Strains		
<i>Listeria monocytogenes</i>	A gift from D. Portnoy	N/A
Biological Samples		
Chemicals, Peptides, and Recombinant Proteins		
Recombinant murine IL- $\beta$	Peptotech	Cat# 211-11B
MitoSOX Red Mitochondrial Superoxide Indicator	ThermoFisher Scientific	Cat# M36008
MitoTracker Deep Red FM	ThermoFisher Scientific	Cat# M22426

REAGENT or RESOURCE	SOURCE	IDENTIFIER
MitoTracker Green FM	ThermoFisher Scientific	Cat# M7514
Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM)	ThermoFisher Scientific	Cat# T668
MitoTEMPO	Millipore Sigma	Cat# SML0737
DAPI, FluoroPure grade	ThermoFisher Scientific	Cat# D21490
ATP	InvivoGen	Cat# TLRL-ATP
Nigericin sodium salt	Millipore Sigma	Cat# N7143
Poly(deoxyadenylic-thymidylic)(dA:dT) acid sodium salt	Millipore Sigma	Cat# P0883-10UN
FlaTOX	von Moltke et al., 2012 (a gift from R. Vance)	N/A
Imject Alum Adjuvant	ThermoFisher Scientific	Cat# 77161
Lipopolysaccharide from <i>E. coli</i> O111:B4	Millipore Sigma	Cat# L4391
25-hydroxycholesterol	Avanti Polar Lipids	Cat# 700019P
Cholesterol-Water Soluble	Millipore Sigma	Cat# C4951
Methyl- $\beta$ -cyclodextrin	Millipore Sigma	Cat# C4555
Rapamycin	LC Laboratories	Cat# R-5000
Cytochalasin D	Millipore Sigma	Cat# C8273
Filipin III from <i>Streptomyces filipinensis</i>	Millipore Sigma	Cat# F4767
Digitonin	Millipore Sigma	Cat# D141
Ethidium bromide	Millipore Sigma	Cat# E1510
2',3'-Dideoxycytidine (ddC)	Millipore Sigma	Cat# D5782
GW3965 hydrochloride	Millipore Sigma	Cat# G6295
Lipoprotein, High Density	Lee Biosolutions	Cat# 361-10-0.01
Brain Heart Infusion Agar, Deep Fill, 15×100mm plate R	Hardy Diagnostics	Cat # W15
Critical Commercial Assays		
Seahorse XF Cell Mitochondria Stress Test Kit	Seahorse Biosciences/Agilent	Cat# 103015-100
MACS Mitochondrial Isolation Kit	Miltenyi Biotec	Cat# 130-096-946
Amplex Red Cholesterol Assay Kit	ThermoFisher Scientific	Cat# A12216
Deposited Data		
Experimental Models: Cell Lines		
Human Embryonic Kidney Cells (HEK293T)	ATCC	Cat# CRL-3216
Platinum-E (Plat-E) Retroviral Packaging Cell Line	A gift some S. Schwab	N/A
Experimental Models: Organisms/Strains		
Mouse: C57BL/6J	Jackson Laboratories	Stock No: 000664
Mouse: B6-Ly5.1/Cr Strain ID: B6.SJL- <i>Ptpr<sup>c</sup>Pepc<sup>b</sup></i> /BoyCrCrI	NCI at Charles River	Stock No: 564
Mouse: Ch25h <sup>-/-</sup> Strain ID: B6.129S6- <i>Ch25h<sup>tm1Rus/J</sup></i>	Jackson Laboratories	Stock No: 016263
Mouse: Aim2 <sup>-/-</sup> Strain ID: B6.129P2- <i>Aim2<sup>Gt(CSG445)Byg/J</sup></i>	Jackson Laboratories	Stock No: 013144
Mouse: Asc <sup>-/-</sup> Strain ID: B6.129-Pycard <sup>tm1Vmd</sup>	Genentech	N/A



REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mouse: <i>Nlrp3</i> <sup>-/-</sup> Strain ID: B6.129S6- <i>Nlrp3</i> <sup>m1Bhk/J</sup>	Jackson Laboratories	Stock No: 021302
Mouse: <i>Casp1</i> <sup>1/11-/-</sup> Strain ID: B6N.129S2- <i>Casp1</i> <sup>m1Flv/J</sup>	Jackson Laboratories	Stock No: 016621
Mouse: <i>Nr1h3</i> <sup>-/-</sup> Strain ID: 129- <i>Nr1h3</i> <sup>m1Djm/J</sup>	Jackson Laboratories	Stock No: 013762
Mouse: <i>Nr1h2</i> <sup>-/-</sup> Strain ID: B6.129S- <i>Nr1h2</i> <sup>m1Djm/J</sup>	Jackson Laboratories	Stock No: 014635
Mouse: <i>Nlr4</i> <sup>-/-</sup> Strain ID: B6N- <i>Nlr4</i> <sup>m1Vmd</sup>	Genentech	N/A
Oligonucleotides		
RT-PCR primers for <i>Ch25h</i> Fwd: 5'-GCGACGCTACAAGATCCA-3' Rev: 5'-CACGAACACCAGGTGCTG-3'	This paper	N/A
RT-PCR primers for <i>Hmgcs1</i> Fwd: 5'-GGAAGCCTTTGGGGACGTTA-3' Rev: 5'-ACACTCCAACCCTCTCCCT-3'	This paper	N/A
RT-PCR primers for <i>Lss</i> Fwd: 5'-GGGCCCTGAATGGAGTAACC-3' Rev: 5'-GTCCTCGATGTGCAAGCCC-3'	This paper	N/A
RT-PCR primers for <i>Dhcr24</i> Fwd: 5'-GGACATCATCCCTTTTCGGCA-3' Rev: 5'-TGGGGTAGACGTGGATGTCA-3'	This paper	N/A
RT-PCR primers for <i>Sqle</i> Fwd: 5'-AGTGAACAAACGAGGCGTCC-3' Rev: 5'-AGCAAGCTTTTCGGAGCTGA-3'	This paper	N/A
RT-PCR primers for <i>Tert</i> nuclear DNA	West et al., 2015	N/A
RT-PCR primers for <i>mtDNA D loop</i>	West et al., 2015	N/A
Recombinant DNA		
MSCV-IRES-Thy1.1	Addgene	Plasmid ID: 17442
Software and Algorithms		
FlowJo v10	FlowJo, LLC	N/A
Prism 6	GraphPad Software	N/A
Other		

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jason G. Cyster (Jason.cyster@ucsf.edu).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Mice**—CD45.1 congenic C57BL/6 (B6) male and female mice, 6–12 weeks old were from National Cancer Institute. *Ch25h*<sup>-/-</sup> mice were backcrossed onto C57BL/6J for 10 generations. *Nr1h2*<sup>-/-</sup>, *Nr1h3*<sup>-/-</sup>, *Nlr4*<sup>-/-</sup>, *Aim2*<sup>-/-</sup>, *Casp11*<sup>-/-</sup>, *Casp1/11*<sup>-/-</sup>, *Asc*<sup>-/-</sup> and *Ifnar1*<sup>-/-</sup> mice have all been previously described. Animals were housed in a specific pathogen-free environment in the Laboratory Animal Research Center at UCSF and all experiments conformed to the ethical principles and guidelines approved by the UCSF Institutional and Animal Care and Use Committee.

**Cells**—Bone marrow cells were grown in DMEM with 10% FBS and 10% M-CSF media in bacterial petri dishes for 6 days, then plated at  $1 \times 10^6$  cells/ml and left to adhere overnight. BMDMs were stimulated with 100ng/ml LPS (*E. coli* 0111:B4; Sigma) for the indicated times. For ELISA detection of IL-1 $\beta$  in response to MCD-Chol (Sigma), BMDMs were primed with 100ng/ml LPS for 4 hr, and then MCD-Chol (100ug/ml unless indicated) was added for the final 4 hr of culture. For other inflammasome activation experiments, ATP (Sigma) was added for the final 45 minutes of culture at a concentration of 5mM, alum (400mg/ml; Pierce) and poly(dA:dT) (1ug/ml; Invivogen) was added for the final 4 hr of culture, and FlaTox (1:100 dilution) was added for the final 45 minutes of culture. For two sets of experiments, rapamycin (20nM) or cytochalasin D (2uM; Sigma) was also added for the final 4 hr of culture.

## METHOD DETAILS

**Bone marrow chimeras**—CD45.1 congenic mice were lethally irradiated with 1,100 rad in split doses 3 hr apart, and reconstituted with  $1-3 \times 10^6$  BM cells per mouse from wild type, *Aim2*<sup>-/-</sup>, *Nlrp3*<sup>-/-</sup>, or *Casp1/11*<sup>-/-</sup>, *Ch25h*<sup>+/-</sup>, *Ch25h*<sup>-/-</sup>, *Ch25h*<sup>+/-</sup>*Aim2*<sup>-/-</sup>, or *Ch25h*<sup>-/-</sup>*Aim2*<sup>-/-</sup> mice. Mice were analyzed 8–10 weeks later.

**BMDM transduction**—BM cells were cultured in DMEM with 10% FBS and 10% M-CSF conditioned medium for 2 days, then spininfected for 2 hr on days 2 and 3 with retroviruses expressing Ch25h, Ch25hmut, Hmgcr, Dhcr24, or control and an IRES-thy1.1 cassette as a reporter. Cells were then plated at  $1 \times 10^6$  cells/ml and left to adhere overnight on day 6. Cells were always cultured in 10% M-CSF conditioned medium.

**Listeria monocytogenes infection of BMDMs**—*L. monocytogenes* single colonies were incubated in brain heart infusion (BHI) broth overnight at 30°C without shaking. Cultures were then diluted 1:10 in BHI broth and incubated at 37°C with shaking. When cultures were in log-phase growth, bacteria were added to BMDMs seeded on TC-treated plates at a multiplicity of infection (MOI) of 10 to 1. After 30 minutes infected cells were washed, and media containing gentamicin (50ug/ml) was added. For CFU determination, cells were lysed in cold ddH<sub>2</sub>O and lysates were streaked onto BHI agar plates.

**Flow cytometry**—Cells were stained with Abs to CD4 (RM4-5), TCR $\beta$  (H57-597), IL-17A (17B7), CD11b (M1/70), or Ly6G (1A8). For mitochondrial studies, cells were treated as indicated and then stained with 30 minutes with Mitotracker Deep Red (100nM), Mitotracker Green (100nM), TMRM (100nM) or MitoSOX (2.5 uM) at 37°C. All mitochondrial staining reagents were from Life Technologies. For intracellular cytochrome C staining, cells were stimulated as indicated and then treated on ice with either control or digitonin (25 ug/ml) for 10 minutes. Cells were then treated with BM Cytotfix Buffer and Perm/Wash reagent (BD Biosciences), and stained with anti-cytochrome C (6H2.B4). Antibodies were purchased from BD Biosciences or eBiosciences.

**IL-1 $\beta$  T cell bioassay**—Peripheral lymph nodes (LNs) and spleens from wild type mice were harvested and mashed through a 70 micron strainer. CD4<sup>+</sup> T cells were enriched by positive selection using CD4<sup>+</sup> MACS beads (Miltenyi). T cells ( $5 \times 10^5$ ) were then cultured

for 4 days in 24-well plates with plate-bound anti-CD3 (2 ug/mL), soluble anti-CD28 (1 ug/mL), and recombinant TGF- $\beta$  (2 ng/mL) and the indicated BMDM supernatants. On day 4, T cells were stimulated with PMA/ionomycin and brefeldin A (BD Biosciences) for 4 hr. Cells were stained with fixable viability dye (eFluor780; eBiosciences) to exclude dead cells, surface stained with Abs to CD4 (RM4-5) and TCR $\beta$  (H57-597), treated with BM Cytotfix Buffer and Perm/Wash reagent (BD Biosciences), and stained with anti-IL-17A (17B7). Antibodies were purchased from BD Biosciences or eBiosciences.

**Cytokine enzyme-linked immunosorbent assays**—Supernatants from cultured BMDMs and serum from LPS-injected mice were collected from the indicated conditions and times points. Unconjugated anti-IL-1 $\beta$  (B122; Biolegend) (2ug/ml) was coated onto 96-well high binding plates and then plates were washed and blocked for 1 hour with PBS containing 5% FBS. Supernatants were added to the plates O/N at 4°C. Plates were washed again and biotinylated anti-IL-1 $\beta$  (polyclonal; eBiosciences) (1ug/ml) was added for 1–2 hr at RT. Biotinylated detection antibodies were then labeled by streptavidin-conjugated horseradish peroxidase (HRP) and visualized by addition of Substrate Reagent Pack (R&D). Color development was stopped by addition of 2N H<sub>2</sub>SO<sub>4</sub>. Recombinant IL-1 $\beta$  (eBiosciences) was used as a standard. Absorbance at 450 nm was measured on a tunable microplate reader (VersaMax, Molecular Devices). Cytokine supernatant concentrations were calculated by extrapolating absorbance values from standard curves where known concentrations were plotted against absorbance using SoftMax Pro 5 software.

**In vivo peritonitis**—For neutrophil recruitment into the peritoneum, mice were injected I.P. with saline containing either LPS (10ug), LPS(10ug)+MCD-Chol(100ug), or LPS +Alum(400ug). 8–10 hr after injection, mice were sacrificed, peritoneal cavities were lavaged using 5 ml of PBS with 1% FBS and 1mM HEPES, and peritoneal cells were analyzed using FACS. For mitochondrial cholesterol measurements and Mitotracker staining on peritoneal macrophages, mice were injected I.P. with saline or LPS (2mg/kg) for 8 hr.

**Quantification of sterols**—BMDMs were treated as indicated, sterols were extracted with organic solvents, and quantitated using a SCIEX API 5000 mass spectrometer coupled to a Shimadzu LC-20XR high performance liquid chromatograph as previously described(McDonald et al., 2012).

**RNA isolation and Real-time RT-PCR**—Total RNA was isolated from 5 $\times$ 10<sup>5</sup> BMDMs treated as indicated with the Trizol reagent (Life Technology) following the manufacturer's protocol. Real-time PCR was performed using SYBR Green PCR Mix (Roche) and an ABI Prism 7300 sequence detection system (Applied Biosystems, Foster City, CA). *Hprt* levels were used as internal controls. Primer sequences are available upon request.

**Seahorse analysis of mitochondrial respiration**—For real-time analysis of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), BMDMs were analyzed with an XF-24 Extracellular Flux Analyzer (Seahorse Bioscience). 2 $\times$ 10<sup>5</sup> BMDMs were plated in Seahorse 24-well plates and the Seahorse XF Cell Mitochondria Stress assay was performed per manufacturer's instructions. Oligomycin was added at 1uM, FCCP at 1uM, and Rotenone/Antimycin A at 0.5uM each (Seahorse Biosciences).

**293T inflammasome reconstitution**— $1.5 \times 10^5$  293T cells were seeded in 24-well plates O/N in DMEM with 10% FBS and antibiotics. The next day, cells were switched to antibiotic-free DMEM with 10% FBS and transfected using Lipofectamine 2000 (Life Technologies) with the indicated plasmids (all 50ng). 24 hr later, cells were stimulated with nigericin (15uM; Sigma) for 45 minutes. Supernatants were then collected, and cells were lysed in RIPA buffer (25mM Tris-HCl pH 7.5, 150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100). Western blots were performed with rabbit polyclonal anti-caspase-1 p10 (M-20, Santa Cruz), mouse monoclonal anti-NLRP3 (Cryo-2, Adipogen), rabbit polyclonal anti-ASC (AL177, Adipogen), and goat anti-IL-1 $\beta$  (polyclonal; R&D).

**Cytosolic and total DNA extraction**— $2 \times 10^6$  BMDMs per well seeded in 6-well plates were stimulated as indicated, washed with ice cold PBS, and scraped off the plates. Cells were then pelleted in a table top centrifuge by spinning at 800g for 5 minutes at 4°C. Cell pellets were resuspended in 500ul of cytosolic extraction buffer (150mM NaCl, 50mM HEPES pH 7.4, 25 ug/ml digitonin) and rotated for 10 minutes at 4°C. Cells were then centrifuged at 800g for 3 minutes. Supernatants were collected and centrifuged at 800g for 3 minutes twice more, followed by a 5 minute centrifugation at 10,000g. DNA was then extracted from the cell pellets and cytosolic fraction using a QIAamp DNA Micro Kit (Qiagen). DNA was quantified using qPCR with mtDNA (*D loop*) and nucDNA (*Tert*) primers; cytosolic DNA signals were normalized to cell pellet DNA signals. Primer sequence are available upon request.

**Mitochondrial DNA depletion**—BMDMs were grown as described above. On day 6, media was replaced with DMEM containing 10% FBS and 10% M-CSF conditioned media containing either ethidium bromide (100ng/ml) or 2',3'-dideoxycytidine (40ug/ml). After 5–7 days, BMDMs were detached and mitochondrial DNA depletion was assessed by total DNA extraction followed by qPCR for mtDNA and nucDNA as described above.

**Amplex Red Cholesterol Quantification**—For total cholesterol content, BMDMs were seeded in 6-well plates at  $2 \times 10^6$  cells per well and stimulated as described. Peritoneal macrophages were sorted using a FACS Aria II (BD Biosciences). Cells were then lysed in 500 ul RIPA buffer. Cholesterol quantification was then performed using the Amplex Red Cholesterol Assay (Life Technologies) per manufacturer's instructions and readout on a Qubit 3.0 Fluorometer (Life Technologies). For mitochondrial cholesterol content, BMDMs were seeded in 10cm dishes at  $1 \times 10^7$  cells per dish and treated as indicated. Mitochondria were then isolated using anti-TOM22 MACS beads with the Mouse Mitochondria Isolation Kit (Miltenyi Biotec) per manufacturer's instructions. Isolated mitochondria were then lysed in 200ul RIPA buffer. Amplex Red fluorescent concentrations were normalized based on total protein content using the BCA Protein Assay Kit (Pierce).

**Confocal microscopy**—BMDMs ( $1 \times 10^5$ ) were seeded on round glass coverslips in 24-well plates overnight and then stimulated with LPS for 8 hr along with 150X FLICA reagent (ImmunoChemistry Technologies). Cells were then fixed with 1% PFA for 20min at 37°C and washed 3x with 1X PBS and stained with DAPI. Images were then taken on a Leica SP5 laser-scanning confocal microscope using a 63X oil immersion lens.

## QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analyses were performed in Graphpad Prism version 6, as defined throughout the text and figure legends.

## DATA AND SOFTWARE AVAILABILITY

The data presented in this manuscript are tabulated in the main paper and in the STAR Methods. The primer sequences used for quantitative RT-PCR are available upon request.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank J. An and Y. Xu for expert technical assistance, A. Ma for *Casp1/11<sup>-/-</sup>*, *Asc<sup>-/-</sup>*, and *Nlrp3<sup>-/-</sup>* bone marrow, T. DeFranco for *Nlr4<sup>-/-</sup>* bone marrow, K. Fitzgerald for *Nlrp3<sup>-/-</sup> Aim2<sup>-/-</sup>* bone marrow, R. Vance for FlaTox, C. Paillart for help with Seahorse setup, and J. Cox, R. Locksley, A. Reboldi, E. Wolf, and J. Wu for helpful discussions. Confocal imaging was supported by UCSF DRC Center grant P30 DK063720. EVD is supported by NIH F30 grant F30AI120527 and the UCSF Medical Scientist Training Program (MSTP) and JGC is an Investigator of the Howard Hughes Medical Institute. This work was supported in part by NIH grants AI040098 (to JGC) and HL20948 (to JGM and DWR).

## References

- Aguirre S, Luthra P, Sanchez-Aparicio MT, Maestre AM, Patel J, Lamothe F, Fredericks AC, Tripathi S, Zhu T, Pintado-Silva J, et al. Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. *Nature Microbiology*. 2017; 2:17037.
- Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, Lacaze P, Watterson S, Griffiths SJ, Spann NJ, et al. The Transcription Factor STAT-1 Couples Macrophage Synthesis of 25-Hydroxycholesterol to the Interferon Antiviral Response. *Immunity*. 2013; 38:106–118. [PubMed: 23273843]
- Bosch M, Marí M, Herms A, Fernández A, Fajardo A, Kassan A, Giralt A, Colell A, Balgoma D, Barbero E, et al. Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. *Curr Biol*. 2011; 21:681–686. [PubMed: 21497090]
- Campos CBL, Paim BA, Cosso RG, Castilho RF, Rottenberg H, Vercesi AE. Method for monitoring of mitochondrial cytochrome C release during cell death: Immunodetection of Cytochrome C by flow cytometry after selective permeabilization of the plasma membrane. *Cytometry*. 2006; 69:515–523. [PubMed: 16680678]
- Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. *J Biol Chem*. 1989; 264:11934–11937. [PubMed: 2745424]
- Cyster JG, Dang EV, Reboldi A, Yi T. 25-Hydroxycholesterols in innate and adaptive immunity. *Nature Reviews Immunology*. 2014; 14:731–743.
- de Luca C, Olefsky JM. Inflammation and insulin resistance. *FEBS Letters*. 2008; 582:97–105. [PubMed: 18053812]
- Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell*. 2010; 39:171–183. [PubMed: 20670887]
- Franklin BS, Mangan MS, Latz E. Crystal Formation in Inflammation. *Ann Rev Immuno*. 2016; 34:173–202.
- Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell*. 2006; 124:35–46. [PubMed: 16413480]


- Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Pasquier Du RA, Romero P, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. *Immunity*. 2011; 34:213–223. [PubMed: 21349431]
- Hayashi T, Su TP. Sigma-1 Receptor Chaperones at the ER-Mitochondrion Interface Regulate Ca<sup>2+</sup> Signaling and Cell Survival. *Cell*. 131:596–610.
- Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nature Immunology*. 2008; 9:847–856. [PubMed: 18604214]
- Kennedy BE, Madreiter CT, Vishnu N, Malli R, Graier WF, Karten B. Adaptations of energy metabolism associated with increased levels of mitochondrial cholesterol in Niemann-Pick type C1-deficient cells. *J Biol Chem*. 2014; 289:16278–16289. [PubMed: 24790103]
- Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, et al. Interferon-Inducible Cholesterol-25-Hydroxylase Broadly Inhibits Viral Entry by Production of 25-Hydroxycholesterol. *Immunity*. 2013; 38:92–105. [PubMed: 23273844]
- Marí M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, García-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. *Cell Metab*. 2006; 4:185–198. [PubMed: 16950136]
- Martin LA, Kennedy BE, Karten B. Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function. *J Bioenerg Biomembr*. 2016; 48:137–151. [PubMed: 25425472]
- McDonald JG, Russell DW. Editorial: 25-Hydroxycholesterol: a new life in immunology. *Journal of Leukocyte Biology*. 2010; 88:1071–1072. [PubMed: 21123296]
- Metherall JE, Ridgway ND, Dawson PA, Goldstein JL, Brown MS. A 25-hydroxycholesterol-resistant cell line deficient in acyl-CoA: cholesterol acyltransferase. *J Biol Chem*. 1991; 266:12734–12740. [PubMed: 1712025]
- Montero J, Marí M, Colell A, Morales A, Basañez G, García-Ruiz C, Fernandez-Checa JC. Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. *Biochim Biophys Acta*. 2010; 1797:1217–1224. [PubMed: 20153716]
- Nakahira K, Haspel JA, Rathinam VAK, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nature Immunology*. 2011; 12:222–230. [PubMed: 21151103]
- Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leever S, Griffiths JR, Chung YL, Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab*. 2008; 8:224–236. [PubMed: 18762023]
- Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. *Annu Rev Immunol*. 2012; 30:39–68. [PubMed: 22136167]
- Rathinam VAK, Fitzgerald KA. Inflammasome Complexes: Emerging Mechanisms and Effector Functions. *Cell*. 2016; 165:792–800. [PubMed: 27153493]
- Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster JG. 25-Hydroxycholesterol suppresses interleukin-1–driven inflammation downstream of type I interferon. *Science*. 2014; 345:679–684. [PubMed: 25104388]
- Robertson KA, Hsieh WY, Forster T, Blanc M, Lu H, Crick PJ, Yutuc E, Watterson S, Martin K, Griffiths SJ, et al. An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway. *PLOS Biology*. 2016; 14:e1002364. [PubMed: 26938778]
- Robinson LE, Shridar M, Smith P, Murrell-Lagnado RD. Plasma membrane cholesterol as a regulator of human and rodent P2X7 receptor activation and sensitization. *J Biol Chem*. 2014; 289:31983–31994. [PubMed: 25281740]
- Rongvaux A, Jackson R, Harman CCD, Li T, West AP, de Zoete MR, Wu Y, Yordy B, Lakhani SA, Kuan CY, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. *Cell*. 2014; 159:1563–1577. [PubMed: 25525875]
- Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity*. 2012; 36:401–414. [PubMed: 22342844]

- Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. *Proc Natl Acad Sci USA*. 2011; 108:15324–15329. [PubMed: 21876127]
- Sun B, Sundstrom KB, Chew JJ, Bist P, Gan ES, Tan HC, Goh KC, Chawla T, Tang CK, Ooi EE. Dengue virus activates cGAS through release of mitochondrial DNA. *Scientific Reports*. 2017; 7:3594. [PubMed: 28620207]
- Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat Med*. 2011; 17:179–188. [PubMed: 21217695]
- West AP, Houry-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, Bestwick M, Duguay BA, Raimundo N, MacDuff DA, et al. Mitochondrial DNA stress primes the antiviral innate immune response. *Nature*. 2015; 520:553–557. [PubMed: 25642965]
- White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, van Delft MF, Bedoui S, Lessene G, Ritchie ME, et al. Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production. *Cell*. 2014; 159:1549–1562. [PubMed: 25525874]
- Wu J, Fernandes-Alnemri T, Alnemri ES. Involvement of the AIM2, NLRC4, and NLRP3 inflammasomes in caspase-1 activation by *Listeria monocytogenes*. *J Clin Immunology*. 2010; 5:693–702.
- York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH, et al. Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling. *Cell*. 2015; 163:1716–1729. [PubMed: 26686653]
- Yu J, Nagasu H, Murakami T, Hoang H, Broderick L, Hoffman HM, Horng T. Inflammasome activation leads to Caspase-1-dependent mitochondrial damage and block of mitophagy. *Proc Natl Acad Sci USA*. 2014; 111:15514–15519. [PubMed: 25313054]
- Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalpour S, Wong J, He F, Boassa D, Perkins G, Ali SR, et al. NF- $\kappa$ B Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. *Cell*. 2016; 164:896–910. [PubMed: 26919428]
- Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. *Nature*. 2011; 475:122–122.

### Highlights


- Ch25h upregulation in activated macrophages restricts cholesterol biosynthesis
- High cholesterol synthesis leads to AIM2-dependent inflammasome activation
- Elevated cholesterol causes impaired mitochondrial metabolism and mtDNA release
- 25-HC maintains mitochondrial integrity and prevents AIM2 inflammasome activation





**Figure 1. Increased IL-1 $\beta$  production and control of *L. monocytogenes* intracellular growth in *Ch25h*<sup>-/-</sup> macrophages involves ASC-dependent inflammasome activation**

IL-1 $\beta$  enzyme-linked immunosorbent assay (ELISA) from supernatants (A, B) and bacterial colony forming units (CFU) from cell lysates (C, D) of control (EtOH) or 25-HC (1 $\mu$ M) treated *Ch25h*<sup>+/-</sup>*Asc*<sup>+/+</sup> and *Ch25h*<sup>-/-</sup>*Asc*<sup>+/+</sup> (A, C) or *Ch25h*<sup>+/-</sup>*Asc*<sup>-/-</sup> and *Ch25h*<sup>-/-</sup>*Asc*<sup>-/-</sup> (B, D) BMDMs after 24 hr of *L. monocytogenes* infection (M.O.I. 10:1). (E) IL-1 $\beta$  ELISA from supernatants of LPS and LPS+ATP stimulated BMDMs of the indicated genotypes. (n=3 per genotype, means $\pm$ SD). \*P<0.05, \*\*P<0.01, \*\*\*P < 0.005 (unpaired Students *t* test). See also Figure S1.



**Figure 2. Ch25h induction prevents cholesterol buildup in macrophages by enforcing repression of mTORC1-dependent SREBP activity**

(A) RT-qPCR analysis of *Ch25h*, *Hmgcs1*, *Lss*, *Dhcr24*, and *Sqle* in *Ch25h+/-* and *Ch25h-/-* BMDMs stimulated with LPS. Data are standardized by comparison to *Hprt*, and A.U. indicates arbitrary unit (means $\pm$ SD from 4 independent experiments). (B) LC-MS

quantification of 25-HC, desmosterol, lanosterol, and 7-dehydrocholesterol in *Ch25h+/-* and *Ch25h-/-* BMDMs stimulated with LPS for 8 hr. Y-axis indicates ng/2 $\times$ 10<sup>6</sup> cells. Data from two independent experiments (mean $\pm$ SD). (C) Quantification of cholesterol content by Amplex Red fluorescence in *Ch25h+/-* and *Ch25h-/-* BMDMs stimulated with LPS. Data from 4 independent experiments (mean $\pm$ SD). (D) FACS-based readout of cholesterol

content by Filipin staining. Representative of three independent experiments (mean $\pm$ SD). (E) GC-MS quantification of cholesterol content in *Ch25h+/-* and *Ch25h-/-* BMDMs

(F) Total S6K1 (M.F.I.). (G) pS6K1 (Thr389) MFI. (H) pS6 (Ser240/244) MFI.


stimulated with LPS for 8 hr (n=3, mean+/-SD). (F) Flow cytometry for pS6K1 (Thr389) and pS6 (S240/244) from BMDMs stimulated with LPS. (G) RT-qPCR analysis of *Hmgcs1* expression in *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs treated with LPS and DMSO or rapamycin. Data from three independent experiments (mean+/-SD). (H) IL-1 $\beta$  ELISA from supernatants of *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs treated with LPS and DMSO or rapamycin, and then with ATP. Data from two independent experiments (mean+/-SD). \*P<0.05, \*\*P<0.01, \*\*\*P < 0.005 (unpaired Students *t* test). See also Figure S1.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




### Figure 3. Increased macrophage cholesterol content promotes crystal-independent inflammasome activation

(A) FACS analysis of FLICA staining on BMDMs transduced with either MSCV-vector, -Hmgcr, or -Dhcr24 retrovirus and stimulated with LPS for 8 hr. Data from 3 independent experiments (mean $\pm$ SD). (B) IL-1 $\beta$  bioactivity detected as percentage of CD4<sup>+</sup> T cells producing IL-17A after culture for 4 days in supernatants from *Asc*<sup>+/+</sup> or *Asc*<sup>-/-</sup> BMDMs transduced and stimulated as in A. Graph is representative of 3 independent experiments (mean $\pm$ SD). (C) IL-1 $\beta$  ELISA of supernatants from BMDMs treated with 4 hr with LPS +MCD-Chol. Data from 6 independent experiments (mean $\pm$ SD). (D) IL-1 $\beta$  bioactivity detected as in (B) with supernatants from BMDMs stimulated for 8 hr with either nil, LPS, LPS+MCD (10 $\mu$ g/ml), or LPS+MCD-Chol (10 $\mu$ g/ml). Data from three independent experiments (mean $\pm$ SD). (E) IL-1 $\beta$  ELISA from supernatants of BMDMs treated with LPS, LPS+MCD-Chol, LPS+Alum or LPS+ATP and with DMSO or cytochalasin D. Data from 3 independent experiments (mean $\pm$ SD). (F) IL-1 $\beta$  ELISA of supernatants from *Ch25h*<sup>-/-</sup> BMDMs transduced with MSCV-vector, -Ch25h, or -Ch25hmut and stimulated with either LPS, LPS+MCD-Chol, or LPS+ATP. Data from four independent experiments (mean $\pm$ SD). \*P<0.05, \*\*P<0.01, \*\*\*P < 0.005 (unpaired Students *t* test or one way ANOVA with bonferroni test). See also Figure S2.




**Figure 4. Cholesterol-dependent inflammasome activation requires AIM2 and redundantly involves NLRP3**

(A) Mitochondrial superoxide levels determined by MitoSOX staining of *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs stimulated for 8 hr with LPS, or LPS+ATP treatment. Data are representative of 6 independent experiments (mean+/-SD). (B) MitoSOX staining of *Ch25h<sup>-/-</sup>* BMDMs transduced with MSCV-vector, -Ch25h, or -Ch25hmut and stimulated as in A. Data from 2 independent experiments (mean+/-SD). (C) MitoSOX staining from BMDMs stimulated for with LPS or LPS+MCD-Chol. Data are representative of 3 independent experiments (mean +/- SD). (D-J) IL-1β ELISA of supernatants from *Nlrp3<sup>+/+</sup>* and *Nlrp3<sup>-/-</sup>* (D), *Asc<sup>+/+</sup>* and *Asc<sup>-/-</sup>* (E), *Casp1/11<sup>+/+</sup>* and *Casp1/11<sup>-/-</sup>* (F), *Nlr4<sup>+/+</sup>* and *Nlr4<sup>-/-</sup>* (G), *Casp11<sup>+/+</sup>* and *Casp11<sup>-/-</sup>* (H), *Aim2<sup>+/+</sup>* and *Aim2<sup>-/-</sup>* (I), or *Nlrp3<sup>+/+</sup>* *Aim2<sup>+/+</sup>* and *Nlrp3<sup>-/-</sup>* *Aim2<sup>-/-</sup>* BMDMs treated as indicated. Data from 2 to 4 experiments (mean+/-SD). \*P<0.05, \*\*P<0.01, \*\*\*P < 0.005 (unpaired Students *t* test or one way ANOVA with bonferroni test). See also Figure S3.



### Figure 5. AIM2 is required for cholesterol-dependent neutrophilic peritonitis

(A) Representative FACS plots of peritoneal Ly6G<sup>+</sup> cells from mice injected I.P. 8 hr earlier with the indicated treatments displaying percentage of Ly6G<sup>+</sup> cells. (B) Number of peritoneal neutrophils from mice as treated in A. (C) Representative FACS plots of peritoneal Ly6G<sup>+</sup> cells from LPS or LPS+MCD-Chol treated wild type or *Aim2*<sup>-/-</sup> BM chimeras. (D) Number of peritoneal neutrophils from mice of the type in C treated with LPS or LPS+MCD-chol for 8 hr. (E) Number of peritoneal neutrophils from wild type mice irradiated and transplanted with either wild type, *Nlrp3*<sup>-/-</sup>, or *Casp1/11*<sup>-/-</sup> BM, and treated as in D. Each dot represents an individual mouse and data are pooled from 3 independent experiments (mean±SD). \*P<0.05, \*\*P<0.01, \*\*\*P<0.005 (unpaired Students *t* test or one way ANOVA with bonferroni test).




**Figure 6. Ch25h-deficient and cholesterol loaded macrophages have impaired mitochondrial metabolism**

(A) (Left) Representative histogram of Mitotracker Deep Red staining on *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs stimulated with LPS for 8 hr. (Right) Summary mean fluorescence intensity (MFI) data from 3 experiments (mean  $\pm$  SD). Representative of 8–10 independent experiments. (B) MFI of Mitotracker Deep Red staining on *Ch25h<sup>-/-</sup>* BMDMs transduced with MSCV-vector, –Ch25h, or –Ch25hmut. Data from 4 independent experiments (mean  $\pm$  SD). (C) (Left) Representative histogram of Mitotracker Green staining on *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs stimulated as above. (Right) Summary MFI data from 3 experiments (mean  $\pm$  SD). Representative of 8–10 independent experiments

(mean  $\pm$  SD). (D) MFI of Mitotracker Green staining on *Ch25h*<sup>-/-</sup> BMDMs transduced with MSCV-vector, -Ch25h, or -Ch25hmut. Data from 4 independent experiments (mean $\pm$ -SD). (E) Representative histogram of TMRM staining on *Ch25h*<sup>+/-</sup> and *Ch25h*<sup>-/-</sup> BMDMs stimulated with LPS for 8 hr. Graph shows summary MFI data from 3 experiments (mean $\pm$ -SD). (F) MFI of TMRM staining on *Ch25h*<sup>-/-</sup> BMDMs transduced with MSCV-vector, -Ch25h, or -Ch25hmut. Data from 2 independent experiments (mean $\pm$ -SD). (G) Seahorse analysis of oxygen consumption rate (OCR) over time from BMDMs pretreated for 8 hr with LPS and after the indicated additional treatments. Data are representative of 3 independent experiments (mean $\pm$ -SD). (H) Seahorse analysis of basal OCR and extracellular acidification rate (ECAR) of *Ch25h*<sup>+/-</sup> and *Ch25h*<sup>-/-</sup> BMDMs stimulated with LPS for 8 hr. Data from 3 independent experiments (mean $\pm$ -SD). (I, J) Mitotracker Deep Red (I) and Mitotracker Green (J) staining of *Ch25h*<sup>+/-</sup> and *Ch25h*<sup>-/-</sup> peritoneal macrophages 8 hr after I.P. saline or LPS injection. Data from 3 independent (n=6-7 mice per group). See also Figure S4.





**Figure 7. Cholesterol buildup in mitochondria causes cytosolic release of mtDNA**  
 (A) Quantification of cholesterol in isolated mitochondria from *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs either untreated or stimulated with LPS for 8 hr. Data from 3 independent experiments (mean $\pm$ SD). (B) Quantification of cholesterol in *Ch25h<sup>-/-</sup>* BMDMs transduced with MSCV-vector, -Ch25h, or -Ch25hmut and treated for 8 hr with LPS. Data from three independent experiments (mean $\pm$ SD). (C) mtDNA (Left) or nucDNA (Right) RT-qPCR from cytosolic extracts derived from *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs treated as above. Data from 4 independent experiments (mean $\pm$ SD). (D) Representation histograms (left) and summary graph (right) of intracellular cyt C staining in *Ch25h<sup>+/-</sup>* and *Ch25h<sup>-/-</sup>* BMDMs stimulated for 8 hr with LPS and either permeabilized with digitonin or not. Data from two independent experiments (mean $\pm$ SD). (E) mtDNA RT-qPCR of total DNA extractions from BMDMs treated for 7 days with either nil, ethidium bromide (EtBr), or ddC. Data from 3 independent experiments (mean $\pm$ SD). (F) IL-1 $\beta$  ELISA from

supernatants of BMDMs depleted of mtDNA as described above, and stimulated with either LPS alone, LPS+MCD-Chol, or LPS+ATP. Data from 3 independent experiments (mean+/-SD). (G) IL-1 $\beta$  bioactivity detected as in Fig. 3 using supernatants from LPS-stimulated BMDMs of the indicated genotypes. Data from three independent experiments (mean+/-SD). (H) IL-1 $\beta$  ELISA of supernatants from BMDMs of the indicated genotypes stimulated with LPS or LPS+ATP. Data from three independent experiments (mean+/-SD). (I) *L. monocytogenes* CFU from BMDMs of the indicated genotypes infected for 24 hr. Data from three independent experiments (mean+/-SD). (J) IL-1 $\beta$  ELISA of serum from mice of the indicated genotypes injected with LPS (20mg/kg) I.V. for 8 hr. Data from three independent experiments (n = 5 to 8 mice per group, mean+/-SD). \*P<0.05, \*\*P<0.01, \*\*\*P < 0.005 (unpaired Students *t* test or one way ANOVA with bonferroni test). See also Figure S5.